Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
04/1996
04/03/1996EP0704211A2 Preventive or alleviating agent for medical symptoms caused by delayed allergy reactions
04/03/1996EP0703902A1 Piperidine derivatives and process for their production
04/03/1996EP0703897A1 Lipoxin compounds
04/03/1996EP0703784A1 Release and mobilisation of haematopoietic cells
04/03/1996EP0703783A1 Hla-a2.1 binding peptides and their uses
04/03/1996EP0458861B1 Composition for reparation and prevention of fibrotic lesions
04/03/1996CN1119856A Inhibitors of HIV reverse transcriptase
04/03/1996CN1119829A Vaccine compositions containing 3-O deacylated monophosphoryl lipid a
04/03/1996CN1031465C DNA clones coding for polypeptides exhibiting human graulocyte macrophage and eosinophil cellular growth factor activity
04/02/1996US5504216 Method for reparing an amorphous sulfonamide
04/02/1996US5504189 Peptides, their preparation and use
04/02/1996US5504093 Administering a carbostyril derivative
04/02/1996US5504084 Pharmaceutical for the treatment of skin disorders
04/02/1996US5504079 Method for immune system activation by administration of a β(1-3) glucan which is produced by Saccharomyces cerevisiae strain R4
04/02/1996US5504068 Topical preparations containing cyclosporin
04/02/1996US5504065 Agent for treating or preventing AIDS using human urine trypsin inhibitor
04/02/1996US5504005 Recombinant mycobacterial vaccine
03/1996
03/28/1996WO1996009380A1 Method of enhancing expression of mhc class i molecules bearing endogenous peptides
03/28/1996WO1996009375A1 Dna encoding human papillomavirus type 6a
03/28/1996WO1996009309A1 The oligosaccharide structure of a ligand for e and p selectin
03/28/1996WO1996009297A1 Compositions and methods for treating mast-cell inflammatory condition
03/28/1996WO1996009071A1 Conjugate consisting of an active substance and a non-exogenous native protein
03/28/1996WO1996009068A1 Photodynamic therapy in selective cell inactivation in blood and treating immune dysfunction diseases
03/28/1996WO1996009060A1 Cell growth regulator
03/28/1996WO1996009038A2 Alteration of activity and/or levels of haem-oxygenase to control inflammation
03/28/1996WO1996007738A3 Modified human c3 proteins
03/28/1996DE4433890A1 Konjugat aus einem Wirkstoff und einem nicht als körperfremd angesehenen, nativen Protein Conjugate of an active agent and a non-prestigious as foreign, native protein
03/28/1996CA2200561A1 Compositions and methods for treating mast-cell inflammatory conditions
03/27/1996EP0702898A1 A process for the production of alkali-treated powder possessing an immunological activity
03/27/1996EP0702725A1 Method for recombinant production of biologically active polypeptides
03/27/1996EP0702692A1 Regulation of antigen presentation
03/27/1996EP0702680A1 2-oxo-1,2,3,4-tetrahydroquinoline derivatives
03/27/1996EP0702678A1 Aniline derivatives
03/27/1996EP0702566A1 Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity
03/27/1996EP0702565A1 CATALASE-BASED ANTI-$i(HELICOBACTER PYLORI) IMMUNISING COMPOSITION
03/27/1996EP0702560A1 Immunologic enhancement with intermittent interleukin-2 therapy
03/27/1996EP0702516A1 Genetic immunization with cationic lipids
03/27/1996EP0262125B1 AICA riboside for the prophylactic treatment of diseases with restricted blood flow.
03/27/1996CN1119459A Process for preparing cancer vaccines
03/27/1996CN1119440A 2,6-diaminopurine derivatives
03/27/1996CN1119191A 15-deoxyspergualin analogs, their method of preparation and their use in therapeutics
03/27/1996CN1119121A Crystalline interleukin-4
03/27/1996CN1031403C Process for preparation of hydroxyalkylfuranyl derivatives
03/26/1996US5502167 CDR grafted humanised chimeric T-cell antibodies
03/26/1996US5502075 Leukotriene-B4 derivatives, process for their production and their use as pharmaceutical agents
03/26/1996US5502072 Substituted oxindoles
03/26/1996CA1338183C Cyclic peptolides
03/23/1996CA2132690A1 Control and modulation of inflammatory response in humans in need of such control and modulation
03/21/1996WO1996008574A1 Novel implant and novel vector for the treatment of acquired diseases
03/21/1996WO1996008480A1 Neurokinin antagonists
03/21/1996WO1996008275A1 Secretory leukocyte protease inhibitor as an inhibitor of tryptase
03/21/1996WO1996008269A1 Inhibition of human rotavirus infection
03/21/1996WO1996008268A1 Inhibition of endothelin-1 to reduce inflammatory processes
03/21/1996WO1996008257A1 Synthetic ganglioside derivatives
03/21/1996CA2200083A1 Neurokinin antagonists
03/21/1996CA2199939A1 Inhibition of endothelin-1 to reduce inflammatory processes
03/21/1996CA2199746A1 Secretory leukocyte protease inhibitor as an inhibitor of tryptase
03/21/1996CA2199707A1 Inhibition of human rotavirus infection
03/20/1996EP0702084A1 Recombinant retroviruses
03/20/1996EP0702012A1 Substituted isoxazole sulfonamides and their use as endothelin antagonists
03/20/1996EP0701818A2 Therapeutic methods using catalytic antibodies
03/20/1996EP0701572A1 Composite synthetic peptide construct eliciting neutralizing antibodies and cytotoxic t lymphocytes against hiv
03/20/1996EP0701569A1 Improved reagents and methods for the diagnosis and treatment of diabetes and stiff man syndrome
03/20/1996EP0701554A1 Novel compounds having a benzisoselen-azoline and -azine structure, method for preparing same and therapeutic uses thereof
03/20/1996EP0701443A1 Terfenadine metabolites and their optically pure isomers for treating allergic disorders
03/20/1996EP0701434A1 Preparations containing silicon dioxide to improve the taste thereof
03/20/1996EP0489072B1 Treatment of chronic inflammatory conditions
03/20/1996CN1119019A Compositions and methods for the treatment of immunomediated inflammatory disorders
03/20/1996CN1118783A A process for preparing novel pyrido (3,2-B)(1,5) benzothiazepines
03/20/1996CN1031344C Process for preparing peptides inhibiting maturation of T-lymphocytes and activity of macrophages
03/19/1996US5500429 Cardiovascular
03/19/1996US5500366 Polynucleotide encoding T-cell epitopes of the protein TraT
03/19/1996CA2109800C N-hydroxyurea derivatives which inhibit lipoxygenase
03/14/1996WO1996007739A2 Interleukin-1 type 3 receptors
03/14/1996WO1996007738A2 Modified human c3 proteins
03/14/1996WO1996007657A1 Pyrimido[5,4-d]pyrimidines, drugs containing these compounds, their use, and process for preparing them
03/14/1996WO1996007428A1 Peptide compositions capable of down regulating an antigen specific immune response
03/14/1996WO1996007427A1 Capsular polysaccharide immunomodulator
03/14/1996WO1996007423A1 Immunomodulating medicinal agent
03/14/1996CA2199609A1 Interleukin-1 type 3 receptors
03/14/1996CA2197888A1 Modified human c3 proteins
03/13/1996EP0700445A1 Stress proteins and uses therefor
03/13/1996EP0700444A1 Immunotoxins comprising gelonin and an antibody
03/13/1996EP0700438A1 Opioid receptors: compositions and methods
03/13/1996EP0700402A1 Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
03/13/1996EP0700398A1 Psoralen derivatives, their preparation and use as medicaments
03/13/1996EP0700388A1 Substituted beta-aryl and beta-heteroaryl-alpha-cyanoacrylamide derivatives as tyrosine kinase inhibitors
03/13/1996EP0700387A1 Salts of substituted heteroaromatic nitrogen compounds, method for their preparation and pharmaceutical compounds containing same
03/13/1996EP0700301A1 Peptides and compounds that bind to elam-1
03/13/1996EP0700297A1 Surrogate tolerogenesis for the development of tolerance to xenografts
03/13/1996EP0700296A1 Use of lignan derivatives for the preparation of pharmaceutical compositions for the treatment of states of amyloidosis
03/13/1996EP0700293A1 Dihydrotestosterone for use in androgenotherapy
03/13/1996EP0561927B1 Pharmaceutical compositions for the treatment of b-cell malignancies
03/13/1996EP0455783B1 Use of nervonic acid and long chain fatty acids for the treatment of demyelinating disorders
03/13/1996EP0439513B1 Composition for inhibiting transmission of aids
03/13/1996EP0436545B1 Therapeutic methods using catalytic antibodies
03/13/1996EP0428602B1 Polypeptides and dna encoding same
03/13/1996CN1118573A Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
03/12/1996US5498745 Antiallergen intermediates, inhibitors of leukotrienes, lipoxygenase inhibitors
03/12/1996CA2077996C Roquinimex for supportive use
1 ... 1056 1057 1058 1059 1060 1061 1062 1063 1064 1065 1066 1067 1068 1069 1070 1071 1072 1073 1074 1075 1076 ... 1172